Sulfinpyrazone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sulfinpyrazone
Sulfinpyrazone.svg
Clinical data
Trade names Apo-sulfinpyrazone
AHFS/Drugs.com Monograph
MedlinePlus a682339
Routes of
administration
oral intravenous
ATC code
Pharmacokinetic data
Protein binding 98–99%
Metabolism hepatic
Excretion renal
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard 100.000.325
Chemical and physical data
Formula C23H20N2O3S
Molar mass 404.48 g/mol
3D model (JSmol)
  (verify)

Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.

Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.

Contraindications[edit]

Sulfinpyrazone must not be used in persons with renal impairment or a history of uric acid kidney stones.[1]

References[edit]

  1. ^ Underwood M (June 2006). "Diagnosis and management of gout". BMJ. 332 (7553): 1315–9. PMC 1473078Freely accessible. PMID 16740561. doi:10.1136/bmj.332.7553.1315.